Michelle M. Chen
Dr. Chen is the chief business officer of DNAtrix, a clinical stage biotech company developing oncolytic virus immunotherapy for cancer. She has a track record of successful leadership roles in business development, marketing and R&D. Most recently she was a business development executive at Hoffmann-La Roche responsible for global oncology licensing, collaborations and M&A. Prior to this role, she led the personalized medicine effort and developed Rx/Dx pharma partnerships in Asia and US on behalf of Ventana (Roche Tissue Dx). Dr. Chen started her biotech career in early drug discovery & development at Scios (now J&J) and later Abgenix (now Amgen) as a group leader. She then went on to gain commercial experience at Agilent Technologies and Applied Biosystems respectively, where she led a dozen of new product launches with P&L responsibility, delivered double-digit revenue growth for the business units of more than $200 million, and helped build a molecular diagnostics start up business at Agilent. Dr. Chen received a PhD in Biochemistry from the University of Washington, followed by the post-doctoral work at UCSF and bioinformatics training at Stanford University.